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Background: APT-1011, a fluticasone propionate orally disintegrating tablet formulation, 
is under investigation for the treatment of eosinophilic oesophagitis (EoE). 
Aims: To evaluate the safety and tolerability of APT-1011 administered to patients with 
EoE and to assess the effect on clinical symptoms of EoE, endoscopic appearance, and 
oesophageal eosinophilia. 
Methods: A randomised, double-blind, placebo-controlled, multicentre, phase 1b/2a 
study was conducted at 7 medical centres in the US to evaluate the safety and 
tolerability of APT-1011 over 8 weeks in adults and adolescents with EoE. Participants 
were randomised to placebo (n=8), 1.5 mg APT-1011 BID (n=8) or 3.0 mg APT-1011 
QD (n=8). Safety and tolerability were assessed as the primary outcome; histologic and 
endoscopic measures were assessed as exploratory outcomes. 
Results: There were no deaths, serious treatment-emergent adverse events (TEAEs), 
severe TEAEs, or discontinuations from the study related to a TEAE. In one participant 
randomised to 1.5 mg APT-1011 BID, a reduction in cortisol was observed, but without 
evidence of adrenal insufficiency. Compared to placebo, treatment with APT-1011 
resulted in greater reductions in oesophageal eosinophil counts, EoE Endoscopic 
Reference Score, patient global assessment, and symptom-based EoE activity index 
from baseline to end of treatment (Week 8). 
Conclusions: APT-1011 was safe and well tolerated in adolescents and adults with EoE. 




findings as well evidence of symptom improvement. The results of this study support the 
continued development of APT-1011 for the treatment of EoE (NCT-01386112). 
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INTRODUCTION 
Although currently classified as an orphan disease, EoE is an increasingly 
prevalent atopic condition characterised by symptoms of oesophageal dysfunction and 
infiltration of eosinophils into the oesophageal mucosa.1–4 Untreated EoE can progress 
from inflammation to a mix of inflammatory and fibrostenotic disease with oesophageal 
remodelling that manifests by subepithelial fibrosis, oesophageal stricture formation, and 
reduced oesophageal distensibility.5–8 In the United States (US) and several countries in 
Western Europe, EoE is now recognised as a leading cause of dysphagia and food 




Currently, there are no US Food and Drug Administration (FDA)-approved 
pharmacologic treatments for EoE, so all pharmaceutical treatments are currently being 
used off-label.10 Elimination diets are considered a first-line treatment option for EoE but 
can adversely affect meal-related quality of life and have demonstrated limited 
sustained adherence in some studies.11,12 Common first-line treatments for EoE are 
swallowed topical corticosteroids, such as fluticasone propionate or budesonide.1,13,14 In 
clinical practice in the US, the available aerosolised or nebulised corticosteroids, 
designed for airway delivery, are ingested by patients. Alternatively, liquid preparations 
of topical corticosteroids, designed for nebuliser use, have been mixed into a viscous 
slurry and swallowed by patients.3,15 While the initial results of swallowed aerosolised 
corticosteroid treatment for EoE have demonstrated efficacy, variation in dose, 
administration technique, and/or compliance can affect the outcomes of therapy.3 
Additionally, administration of swallowed aerosolised topical corticosteroids may be 
suboptimal for treatment of EoE, as the aerosolised preparation is delivered to both the 
lungs and the oesophagus.16 Oral drug delivery and formulation can also have an effect 
on relevant outcomes, such as complete histologic remission, as seen with a swallowed 
viscous liquid vs a swallowed, nebulised preparation of budesonide (64% vs 27%).16 
APT-1011 is a fluticasone propionate tablet that dissolves in the mouth and is 
swallowed without liquids. APT-1011 was developed to specifically address the unmet 
therapeutic need for EoE. The objectives of this proof-of-concept study were to evaluate 
the safety and tolerability of 2 dosing regimens of APT-1011 administered orally to 
patients with EoE and to assess the effect of APT-1011 on clinical symptoms of EoE, 





A randomised, double-blind, placebo-controlled, multicentre, phase 1b/2a study 
was conducted at 7 medical centres in the US to evaluate the safety and tolerability of 
APT-1011 (Adare Pharmaceuticals, Inc, Lawrenceville, NJ [formerly Aptalis Pharma US, 
Inc.]) over 8 weeks in adults and adolescents with EoE (ClinicalTrials.gov registration 
#NCT01386112). The study was conducted in accordance with the principles set forth in 
the Declaration of Helsinki and in compliance with International Conference on 
Harmonization—Good Clinical Practice standards. The study protocol was approved by 
Copernicus Group Independent Review Board (protocol #PR-021; 01 September 2011).  
Eligibility Criteria 
Eligible patients between 12 and 55 years age had histologically confirmed EoE 
(oesophageal mucosal peak eosinophil count ≥ 24 per high-power field (HPF) [HPF; 
radius=0.275 mm; 400×] in at least 1 biopsied site, within 30 days prior to and 21 days 
after the screening visit), histologically confirmed prior treatment failure of a high-dose 
proton pump inhibitor (PPI), defined as peak eosinophil counts ≥24 per HPF after 8 
weeks of 2× standard PPI dose per investigator, and at least one of the following 
symptoms: chest pain or discomfort, dysphagia, or food impaction continuously or 
intermittently present within 30 days prior to the screening visit. Specific symptom 
severity was not required for this study. Females of childbearing potential must have 
agreed to use adequate contraception during the study and could not be pregnant or 
lactating at time of enrolment. Written informed consent was obtained from each 




Patients were excluded from participating in the study if they met any of the 
following criteria: presence of any condition, other than EoE, that affected the 
oesophageal mucosa or motility; any contraindication to completing 
oesophagogastroduodenoscopy, including stricture that blocked the passage of a 
standard endoscope; history or presence of Crohn’s disease, celiac disease, or other 
gastrointestinal inflammatory disease; use of systemic, inhaled, intranasal, or high-
potency dermal topical corticosteroids during the 30 days prior to enrolment; morning 
serum cortisol level ≤ 5 µg/dL; or use of anti-inflammatory or immunosuppressant drugs. 
Randomisation 
Participants were randomised 1:1:1 to APT-1011 at 1.5 mg BID, APT-1011 at 3.0 
mg QD, or placebo by a blinded study coordinator, according to a computer-generated 
list of randomisation numbers, with a block size of 3. A unique randomisation number 
was assigned to each participant in sequential order of enrolment. All study site 
personnel, including the endoscopist, the central pathologist, the 
participants/caregivers, and the sponsor, were blinded to the treatment groups.  
Interventions 
Participants were given 2 bottles—1 for the morning dose, and 1 for the evening 
dose—and were instructed to take their morning dose at least 30 minutes before food 
intake and their evening dose at least 30 minutes after a meal. Participants were 
instructed not to drink or eat for 30 minutes after each dose. The placebo group had a 
placebo tablet in both morning and evening bottles; the APT-1011 1.5 mg BID group 




APT-1011 3.0 mg QD group had a placebo tablet in the morning bottle, and a 3.0-mg 
fluticasone propionate tablet in the evening bottle. Participants were instructed to place 
the tablet on the tongue until it dissolved completely and to swallow until it was 
completely ingested (i.e. no visible drug), then to thoroughly rinse mouth with water (i.e., 
rinse and spit) to remove any residual fluticasone propionate from the oral cavity. 
Participants were allowed to continue PPI therapy if they met the histology inclusion 
criteria above (oesophageal mucosal peak eosinophil count ≥ 24 per HPF) and had a 
stable PPI dose for at least 30 days prior to study enrolment. Antihistamines were 
permitted if the participant required them for a medical condition. 
Endpoints 
The primary endpoint was safety and tolerability of APT-1011, as assessed by 
treatment-emergent adverse events (TEAEs), morning serum cortisol and salivary 
cortisol levels, laboratory tests (haematology, serum chemistry, liver function tests, 
urinalysis, and urine chemistry), physical examination, and vital signs at Weeks 2, 4, 6, 
8, and at follow-up.  
Exploratory efficacy endpoints were also measured. At screening and at Week 8, 
participants underwent oesophagogastroduodenoscopy during which 2 to 4 biopsies 
from the distal, middle and/or the proximal oesophagus were taken. Oesophageal 
eosinophil counts per HPF in all parts of the oesophagus were assessed. Endoscopic 
appearance of the oesophagus was evaluated by a treatment-blinded endoscopist. The 
endoscopist graded the presence and severity of oedema (decreased vascular 




accordance with the endoscopic reference score (EREFS) grading and classification 
system.17 Total EREFS was calculated by summing the severity scores of the individual 
components (oedema 0-1, rings 0-3, exudates 0-2, furrows 0-2, strictures 0-1) assessed 
separately for both the proximal and distal oesophagus (ranges 0-18, with higher scores 
indicating more severe endoscopic findings). 
Questionnaires developed for the Eosinophilic Esophagitis Activity Index (EEsAI) 
study were adapted for use in this clinical trial. The following were completed 
prospectively by the study participants and the physicians18: EREFS grading and 
classification system completed by the endoscopist at screening and at Week 8; 
Physician Global Assessment completed by the investigator at randomisation, Week 4, 
and Week 8; EEsAI patient-reported outcomes (PRO) instrument18 with 7-day recall 
period, and Patient Global Assessment with 7-day recall period completed at 
randomisation, Week 4, and Week 8 by the patient; and Pathologist Questionnaire 
(querying presence of various histologic features in biopsies obtained in distal, proximal, 
and/or middle part of the oesophagus) completed at screening and at Week 8. 
The Physician Global Assessment of the participant’s overall EoE activity (Likert 
scale 0–10, where 0 signifies no EoE activity and 10 represents the most severe EoE 
activity) takes into account participant-reported symptoms, endoscopic findings, and 
histologic activity. Study participants provided the Patient Global Assessment of 
symptom severity and EEsAI PRO (score range 0–100, score increases with increasing 
symptom severity)18 at randomisation, Week 4, and Week 8. Participants also 
completed the Mayo Dysphagia Questionnaire-3019,20 and the Gastrointestinal Symptom 





All statistical analyses were performed using the statistical program R (version 
R3.3.1). 
The sample size of 24 participants (8 per group) was expected to provide 
sufficient observation to assess safety and tolerability. As formal sample size 
calculations were not performed for the study, the analyses presented here can only be 
considered directional. All efficacy analyses are based on the intent-to-treat (ITT) 
population. All randomised participants received at least 1 dose of a study drug, had at 
least 1 efficacy measure, and were included in all safety and efficacy analyses.  
TEAEs were summarised by treatment group, according to preferred term from 
the Medical Dictionary for Regulatory Activities (MedDRA, version 14.0). 
As per protocol, the mean, median, min, and max values of distal and proximal 
eosinophil counts per HPF (for subjects in whom these values were available and 
stratified by participant treatment group) are reported at baseline and at Week 8. 
Change over time in the mean and median values of these counts also are presented. A 
participant was considered to show a response to treatment if the peak eosinophil count 
decreased from >24 to <15 eosinophils/HPF and a complete response if the peak 
eosinophil count decreased from >24 to 0 eosinophils/HPF at Week 8. 
Additional exploratory post-hoc analyses were carried out in line with current 
reporting standards. Study participants were first categorized into 3 treatment groups: 
placebo, APT-1011 at 1.5 mg BID, and APT-1011 at 3.0 mg QD. We also categorized 




BID and the APT-1011 at 3.0 mg QD groups combined). For each patient at each visit 
we calculated the mean and median value of the EREFS, the EEsAI PRO score 
(scoring system was published after protocol development and study completion), and 
the overall inflammatory burden by taking peak eosinophils/HPF value from proximal, 
middle, and distal oesophagus. Changes in EREFS, EEsAI PRO score, Patient Global 
Assessment, and maximum peak oesophageal eosinophils/HPF from baseline to Week 
8 were calculated as the difference between the value observed at Week 8 and 
baseline. The variation in these changes was analysed using linear regression models 
that included the effect of treatment with APT-1011 (relative to placebo) and adjustment 
for the baseline value. We first investigated the effect of treatment on the change in 
these values by comparing the patients from the 3 treatment groups: placebo, APT-
1011 at 1.5 mg BID, and APT-1011 at 3.0 mg QD. Additionally, we combined the 
patients from both APT-1011–treated groups. We compared the change in values in 
APT-1011–treated patients with those in placebo group. A P-value of <.05 was 






The study was performed between October 2011 and October 2012. Twenty-four 
participants were randomised, and 22 participants completed the study (Figure 1). 
Demographic and baseline characteristics were largely similar between the treatment 
groups (Table 1); however, there was a higher percentage of participants in the placebo 
group who experienced continuous dysphagia. More than half of the participants 
continued to use PPI therapy during the study. 
Safety and Tolerability 
There were no deaths, serious TEAEs, severe TEAEs, or discontinuations from 
the study related to a TEAE. A total of 41 TEAEs were reported by 18 participants: 12 
participants receiving APT-1011 reported 26 TEAEs, and 6 participants receiving 
placebo reported 15 TEAEs. Two participants on placebo discontinued due to TEAEs. A 
total of 3 TEAEs were considered by a treatment-blinded investigator to be possibly 
related to the study drug: 2 participants receiving APT-1011 at 3.0 mg QD and 1 
participant receiving placebo reported a TEAE of decreased blood cortisol (Table 2). 
Two participants had an adverse event of special interest, adrenal suppression: 1 
participant receiving placebo and 1 participant receiving APT-1011 at 1.5 mg BID. In the 
participant receiving APT-1011 at 1.5 mg BID, serum cortisol levels were 27.7 µg/dL at 
baseline and 4.8 µg/dL at Day 27. The participant did not report any associated 
symptoms or signs of adrenal insufficiency, and results of a subsequent 
adrenocorticotropic hormone stimulation test were within normal limits. The adverse 




The participant receiving placebo who had adrenal suppression had used systemic 
steroid therapy, in violation of the study protocol, and had a serum cortisol of 2.6 μg/dL; 
this participant was diagnosed with adrenal insufficiency unrelated to study drug. 
There were no reports of oral or oesophageal candidiasis in either APT-1011 
treatment group or the placebo group. Besides the changes in cortisol levels described 
above, there were no clinically meaningful changes in laboratory values, vital signs, or 




The mean/median eosinophil counts in the proximal and distal oesophagus and 
changes in these values from baseline to Week 8 in the ITT population are shown in 
Table 3. The median peak eosinophils/HPF in patients who received APT-1011 at 1.5 
mg BID was reduced by 92% in the distal oesophagus and by 100% in the proximal 
oesophagus from screening to Week 8 (Distal eosinophils/HPF: screening = 39.0, Week 
8 = 3.0; proximal eosinophils/HPF: screening = 47.0, Week 8 = 0). The median peak 
eosinophils/HPF in participants who received APT-1011 at 3.0 mg QD was reduced by 
63% in the distal oesophagus and by 97% in the proximal oesophagus from screening 
to Week 8 (Distal eosinophils/HPF: screening = 65.5, Week 8 = 24.5; proximal 
eosinophils/HPF: screening = 29.5, Week 8 = 1.0). With placebo treatment, reductions 
in eosinophil counts over 8 weeks were less than in the active treatment groups (12% 




proximal oesophagus). Histologic response rates based on a reduction from ≥24 
eosinophils/HPF at screening to ≤15 eosinophils/HPF at Week 8 and a complete 
histologic response (0 eosinophils/HPF) at Week 8 are shown in Figure 2A. 
Post-hoc Analyses 
The maximal peak eosinophils/HPF in the oesophagus overall at baseline and Week 8 
is shown in Figure 2B (baseline values are shown in Supplementary Table 1). When 
comparing each of the APT-1011–treated groups to placebo, differences in changes in 
maximal eosinophils/HPF from baseline to end of treatment were observed. Participants 
treated with APT-1011 at 1.5 mg BID had a greater reduction in eosinophils/HPF from 
baseline than placebo-treated participants (coefficient, -47.05; 95% confidence interval 
[CI]: -82.67, -1.02; P = .012). Participants treated with APT-1011 at 3.0 mg QD had a 
greater reduction in eosinophils/HPF from baseline than placebo-treated participants 
(coefficient, -38.2; 95% CI: -73.94, -1.02; P = .037). 
The results of linear regression analyses for changes in maximal peak eosinophils/HPF 
in combined APT-1011–treated groups relative to the placebo-treated group are shown 
in Supplementary Table 2. 
Endoscopic Appearance 
Prespecified analyses 
Endoscopic features reflecting acute inflammation (including oedema, exudates, 
and furrowing) demonstrated the greatest differences between placebo- and APT-1011–
treated participants, as shown in Supplementary Table 3. Whereas oedema and 




these endoscopic features were less likely to be present among APT-1011–treated 
participants at Week 8 compared to baseline. Study participants were less likely to have 
white exudates at week 8 compared to baseline; white exudates were absent in APT-
1011–treated participants at Week 8. 
Post-hoc analyses 
Median EREFS values observed in the different groups and at different visits are 
presented in Figure 2C (baseline values are shown in Supplementary Table 1). When 
comparing each of the APT-1011–treated groups to placebo, differences in EREFS from 
baseline to end of treatment were observed (on average, a decrease of 2.92 points 
[95% CI: -4.68, -0.88] in the APT-1011 at 1.5 mg BID group relative to placebo [P = 
.002] and a decrease of 2.74 points [95% CI: -4.5, -0.88] in the APT-1011 at 3.0 mg QD 
group relative to placebo [P = .004]). The results of linear regression analysis for 
changes in EREFS in the combined APT-1011–treated group relative to the placebo-
treated group are shown in Supplementary Table 2. 
Symptoms 
Prespecified analyses 
Dysphagia was not a required symptom for entry into the study (patients were 
eligible if they had at least one of the following symptoms: chest pain or discomfort 
[58%], dysphagia [84%], or food impaction [33%]) at baseline. The data on participants’ 
symptoms, as measured by the Patient Global Assessment of EoE symptom severity, 






When comparing each of the APT-1011–treated groups to placebo, differences in 
changes in Patient Global Assessment of EoE symptom severity from baseline to end of 
treatment were observed (on average, a decrease of 2.4 points [95% CI: -4.04, -1.21] in 
the APT-1011 at 1.5 mg BID group relative to placebo [P = .006] and a decrease of 1.55 
points [95% CI: -3.17, -1.21] in the APT-1011 at 3.0 mg QD group relative to placebo  
[P = .061]). 
EEsAI PRO symptom scores were calculated in 23 patients (1 placebo patient 
was missing frequency of dysphagia information at end of treatment) (baseline values 
are shown in Supplementary Table 1). Trends toward significant changes in EEsAI PRO 
in the drug-treated group relative to the placebo group were observed (on average, a 
decrease of 15.13 points [95% CI: -33.5, -1.07] in the APT-1011 at 1.5 mg BID group 
relative to placebo [P = .1] and a decrease of 13.27 points [95% CI: -29.87, -1.07] in the 
APT-1011 at 3.0 mg QD group relative to placebo [P = .11]). 
 The data on the percentage of patients in clinical remission (based on EEsAI 
PRO <20) and patients free of dysphagia over the last 7 days are shown in Figures 3B 
and 3C. Compared to baseline, an additional 4 patients in the APT-1011 at 1.5 mg BID 
group (in addition to 3 patients with no dysphagia at baseline) and 2 patients in the 
APT-1011 at 3.0 mg QD group (in addition to 1 patient with no dysphagia at baseline) 
were free of dysphagia in the 7 days prior to the endoscopy visit. No patient had 
complete resolution of dysphagia as assessed by EEsAI PRO in the placebo group (1 




groups. Although the percentage of participants without trouble swallowing during the 
week prior to the end of treatment was greater in participants treated with APT-1011, 
these data should be interpreted with caution given the variability in dysphagia 
frequency/symptoms severity between the different groups at baseline. 
Data from the Gastrointestinal Symptom Rating Scale Questionnaire and Mayo 
Dysphagia Questionnaire did not demonstrate any meaningful changes (data not 
shown). 
DISCUSSION 
Prior studies of fluticasone in EoE have relied on oral administration of 
preparations that are designed for airway delivery in the treatment of asthma. Despite 
the length of time from completion to its publication, this phase 1b/2a, double-blind, 
placebo-controlled, proof-of-concept trial represents a novel evaluation of an orally 
disintegrating tablet formulation of fluticasone, called APT-1011, which was specifically 
designed for the treatment of EoE. As the primary endpoint of this proof-of-concept 
study, there were no safety issues noted with either dose of APT-1011 compared to 
placebo. Additionally, 75% and 63% of participants receiving APT-1011 at 1.5 mg BID 
and APT-1011 at 3.0 mg QD, respectively, achieved a reduction in inflammation to <15 
eosinophils/HPF compared to only 13% of participants treated with placebo. We 
observed a greater improvement in maximal oesophageal eosinophilia, EREFS, Patient 
Global Assessment, and EEsAI PRO (trend) in APT-1011 treatment groups compared 
to placebo. No participants had complete resolution of dysphagia as assessed by EEsAI 




achieved complete resolution of dysphagia symptoms. Given the small sample size and 
imbalances in symptom severity at baseline, particularly as some subjects experienced 
no dysphagia at randomisation, the data on clinical remission should be interpreted with 
caution. 
APT-1011 was well tolerated, without demonstrable safety concerns with dosing 
at 1.5 mg BID and 3.0 mg QD for 8 weeks in adolescents and adults with EoE. 
Specifically, no participant who received active drug developed clinical manifestations of 
adrenal suppression or oral/oesophageal candidiasis in this small phase 1b/2a study. 
This safety profile is particularly relevant as the dose of fluticasone studied is higher 
than those currently used in clinical practice for EoE with swallowed asthma 
formulations of fluticasone (440 µg to 880 µg BID).22 Measurable systemic side effects 
of oral fluticasone propionate therapy are not expected, because the absolute systemic 
bioavailability of orally administered fluticasone propionate is negligible (<1%) compared 
to inhaled fluticasone propionate (16.6%).23,24 Ongoing clinical trials of swallowed 
topical corticosteroids are examining multiple aspects of safety, including adrenal 
function, in the context of long-term maintenance therapy. 
Swallowed topical corticosteroids are the most commonly used medical therapy 
for the management of children and adults with EoE. Previous double-blind, placebo-
controlled trials have demonstrated histologic improvement in oesophageal mucosal 
eosinophil density.3,4,25 Three trials evaluated fluticasone using an inhaler formulation of 
fluticasone propionate designed for asthma, and 2 trials were performed in children with 
EoE. One trial of fluticasone in adults identified a significant reduction in eosinophil 




treatment period.26 Recently, use of fluticasone powder extracted from the diskus 
formation of fluticasone for asthma was reported as an effective alternative to the 
metered-dose formulation in an uncontrolled study of 40 adults with EoE.27 While topical 
corticosteroid preparations have not yet been approved by the US FDA, budesonide in 
an orally disintegrating tablet formulation was recently approved by the European 
Medicines Agency for the treatment of EoE.28 
Disparate histologic definitions of therapeutic response were reported in prior 
studies of topical corticosteroids. On the basis of a histologic threshold of 
<15 eosinophils/HPF, response rates were highly variable, ranging from 50% to 90% of 
participants.26,29 Reasons for this variation are being studied, but they may be related to 
differences in the phenotypic severity of EoE, use of concomitant medications, different 
doses of corticosteroids, or use of corticosteroid formulations that are optimised for 
oesophageal delivery. Potential genetic variation in corticosteroid metabolism and 
patient adherence are additional factors that may impact efficacy. In the current study, 
APT-1011 achieved a histologic response <15 eosinophils/HPF in 75% of participants, 
which supports the effectiveness of the novel delivery system, especially when 
combined with the observed improvement in endoscopic outcomes. 
Although a small number of participants were recruited in this proof-of-concept 
study to assess the short-term safety of APT-1011, study results show improvements in 
histology and endoscopy outcomes. The results should be interpreted with a number of 
considerations in mind. The diagnostic threshold of 24 eosinophils/HPF used in the 
study exceeded the guideline-based criteria of ≥15 eosinophils/HPF. At the time of this 




diagnostic-threshold criteria were followed in this trial to reduce the chance of including 
patients with borderline EoE activity. While we excluded patients with PPI-responsive 
oesophageal eosinophilia (PPI-REE), a large percentage of patients (66.7%) continued 
PPIs. The continued use of PPIs in this group of patients may have reflected the 
presence of concomitant gastro-oesophageal reflux disease. The role of dual therapy is 
still unclear in the management of EoE and is an area of active investigation. Dysphagia 
was not a required symptom for the purposes of study inclusion. For entry into this trial, 
no validated PRO instrument for assessment of EoE symptoms in adolescents and 
adults was used, as no such instrument was available when the trial was designed. The 
EEsAI PRO instrument used in this study was in an early stage of development for adult 
use. One participant in the placebo group violated the study protocol by taking 
exogenous corticosteroids for lumbar disc disease; this participant exhibited a profound 
decrease in oesophageal eosinophilia and severity of endoscopic findings from baseline 
to end of treatment. Finally, patients with PPI-REE were excluded based on 2007 and 
2011 consensus guidelines for the diagnosis of EoE.30,31  The recently published 
AGREE (A Working Group on PPI-REE) statement removed the PPI response criterion 
for EoE diagnosis, making PPI-REE part of the EoE spectrum.4 It remains unclear 
whether the revised criteria will alter the therapeutic efficacy of medical therapies, as 
prior trials have excluded patients with PPI-REE.  
In conclusion, APT-1011, a novel, orally disintegrating tablet formulation of 
fluticasone, was safe and well tolerated in adolescents and adults with EoE. Exploratory 




findings as well as symptoms. The results of this study support the continued 
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Table 1. Demographic and Baseline Characteristics, ITT Population 
 Placebo (n=8) 
APT-1011  
1.5 mg BID (n=8) 
APT-1011  
3.0 mg QD (n=8) 
Age (years), mean (SD) 29.8 (13.9) 23.4 (11.3) 24.6 (10.6) 
Adolescent, n 2 3 3 
Adult 6 5 5 
Male, n (%) 5 (62.5) 4 (50.0) 6 (75.0) 
BMI (kg/m2), mean (SD) 23.5 (3.2) 18.8 (2.7) 24.0 (5.6) 
PPI use, n (%)    
Current 6 (75) 5 (62.5) 5 (62.5) 
Prior 2 (25) 3 (37.5) 3 (37.5) 
Chest pain/discomfort, n    
None 3 5 2 
Intermittent 5 3 6 
Continuous 0 0 0 
Dysphagia, n    
None 2 1 1 
Intermittent 3 7 6 
Continuous 3 0 1 
Food impaction, n    
None 4 4 8 
Intermittent 3 4 0 
Continuous 1 0 0 
Abbreviations: BID, twice daily; BMI, body mass index; ITT, intent-to-treat; PPI, proton 





Table 2. Treatment-Emergent Adverse Events Occurring in ≥2 Participants in Any 





1.5 mg BID (n=8) 
APT-1011  
3.0 mg QD (n=8) 
Any TEAE 6 (75) 6 (75) 6 (75) 
Blood cortisol decreased 2 (25) 3 (37.5) 1 (12.5) 
Diarrhoea 0 0 2 (25) 
Nasopharyngitis 0 1 (12.5) 1 (12.5) 
Abbreviations: BID, twice daily; ITT, intent-to-treat; QD, once daily; TEAE, treatment-





Table 3. Eosinophil Counts per High-Power Field (400×; 0.275 mm radius) in the Distal 
and Proximal Oesophagus 
  Placebo APT-1011 APT-1011 
    1.5 mg BID 3.0 mg QD 
Distal Oesophagus       
Number of patients with 
oesophageal biopsies 8 8 8 
Baseline    
mean eos/HPF 73.1 39.4 66.1 
min-max eos/HPF 28-140 0-96 30-148 
median eos/HPF 55.5 39.0 65.5 
Week 8/end of treatment    
mean change -14.3 -32.0 -46.6 
mean % change -20% -81% -70% 
median change -6.5 -36.0 -41.0 
median % change -12% -92% -63% 
Proximal Oesophagus       
Number patients with 
oesophageal biopsies 5 5 4 
Baseline    
mean eos/HPF 54.6 63.8 34.5 
min-max eos/HPF 0-98 28-107 11-68 
median eos/HPF 72 47.0 29.5 
Week 8/end of treatment    
mean change -14.8 -63.8 -34.0 
mean % change -27% -100% -99% 
median change 0.0 -47.0 -28.5 
median % change 0% -100% -97% 







Figure 1. Study flow diagram. 
Abbreviations: BID, twice daily; QD, once daily. 
 
Figure 2. Percent of participants with treatment response from >24 to <15 
eosinophils/HPF and >24 to 0 eosinophilic per HPF (A), median maximum peak 
oesophageal eosinophils/HPF in the oesophagus overall (B), and median total EREFS 
in patients treated with placebo, APT-1011 at 1.5 mg BID, and APT-1011 at 3.0 mg QD 
(C). 
Abbreviations: BID, twice daily; HPF, high-power field; QD, once daily. 
 
Figure 3. Patient Global Assessment of Symptom Severity (A), percentage of patients 
in remission based on EEsAI PRO <20 (B), and percentage of patients free of 
dysphagia in the past 7 days (C). 
Abbreviations: BID, twice daily; EEsAI PRO, Eosinophilic Esophagitis Activity Index 
patient-reported outcomes; QD, once daily. 
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